Opioid analgesic drug policy (extended-release and special formulations)
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Iowa Policy 05.02.35 alerts
Get alerted when Policy 05.02.35 changes without checking for updates manually.
Monitor payer policy activity
Defines clinical indications and limitations of use for multiple opioid formulations (buprenorphine products, tramadol ER, fentanyl transdermal, hydromorphone ER, hydrocodone ER, methadone formulations) for Wellmark members; affects prescribers and coverage determinations under member benefit contracts.
No material clinical or coverage changes in this revision.
Coverage Criteria for Long‑Acting and Special Opioid Formulations
General coverage criteria for long‑acting opioid formulations
Covered when ALL of the following are met
Repeated across multiple product sections (e.g., Belbuca/Butrans, ConZip, Duragesic, fentanyl transdermal, hydromorphone ER, Hysingla ER, methadone formulations).
See opioid-tolerant definition in clinical rationale/product labeling.
Statement repeated for multiple products across the policy.
Methadone indications and limitations
Additional methadone-specific conditions
From product indications for methadone injection, oral solution, tablets, and intensol.
Reflects FDA-labeled limitations and 42 CFR distribution requirements.
Prior Authorization Coverage Criteria
Covered with prior authorization when the following criteria are met:
Preserves OR condition for cancer/sickle cell/palliative vs chronic severe pain.
All monitoring elements required per clinical rationale.
Coverage criteria for ER opioid prescriptions
Covered when ALL of the following are met (with some OR branches noted):
From clinical rationale and coverage criteria.
Monitoring and reassessment expectations from policy.
Continuation criteria to demonstrate recent use/stability.
Methadone addiction-treatment uses are excluded from these prescribing conditions.
Coverage criteria
Coverage of ER opioids is subject to the following conditions:
Based on product labeling, FDA guidance, and standards of medical practice.
Clinical rationale specifies prior 365-day lookback for routing to prescription benefit.
Triggers application of initial quantity limit criteria (Column A/Column B).
Initial limits and chronic pain approval
Covered when criteria for prior opioid exposure or PA approval are met
Claims will reject and prompt for prior authorization if these are not present.
Reflects limited evidence for long-term opioid benefit and clinical rationale.
Step therapy and post‑limit exceptions
Exceptions where step therapy and post‑limit quantities do not apply
Per CDC and NCCN guidance referenced in clinical rationale.
Per NHLBI guidance referenced in clinical rationale.
Injectable methadone products are not approved for outpatient treatment of opioid dependence and, per product limitations, parenteral methadone should be reserved for patients unable to take oral medication (for example, hospitalized patients). Methadone used for addiction treatment is subject to federal distribution and use conditions (42 CFR) and is not eligible under the outpatient prescribing conditions described in this policy.
Extended‑release and long‑acting opioid products are not indicated for as‑needed (PRN) analgesia. These agents are reserved for patients for whom alternative analgesic options (for example, nonopioid analgesics or immediate‑release opioids) are ineffective, not tolerated, or otherwise inadequate to manage pain sufficiently; use as PRN therapy would be inconsistent with labeled indications and is not supported by the policy.
When methadone is prescribed, it must be for pain management indications described in product labeling; methadone prescribed for detoxification or as maintenance treatment for opioid/substance use disorder is excluded from the outpatient prescribing conditions in this policy. Treatment of opioid addiction with methadone is governed by federal requirements and certified opioid treatment program processes and is not covered under the standard ER/long‑acting opioid coverage criteria.
The CDC opioid prescribing guideline recommendations do not apply to pain related to cancer, sickle cell disease, or patients receiving palliative or end‑of‑life care. For these patients, alternate guidance (for example, NCCN cancer pain and palliative care recommendations) informs clinical decision‑making and benefit routing.
Step therapy requirements and post‑limit quantity restrictions do not apply for patients identified as having cancer, sickle cell disease, or who are receiving palliative/hospice care. Identification may be by recent cancer or sickle cell drug claims, relevant ICD‑10 diagnosis codes, or hospice residence coding in the member profile or claims history within the prior 365 days.
Use of extended‑release/long‑acting opioid formulations as PRN (as‑needed) analgesics is not an indicated use and is considered not medically necessary. These formulations are intended for daily, around‑the‑clock long‑term treatment when alternatives fail, and PRN prescribing contradicts product labeling and policy intent.
Requests that exceed established quantity limits without an approved prior authorization, or requests that do not meet continuation, indication, or monitoring documentation requirements, may be considered not medically necessary. The quantity‑limit chart and prior authorization rules govern approvals for supplies that exceed initial limits or correspond to higher MME/day thresholds.
Coding, Look‑back and MME Thresholds
| ICD-10 (cancer/sickle cell/palliative care) | Claims submitted with ICD-10 diagnosis codes indicating cancer, sickle cell disease, or palliative care will be paid under prescription benefit. |
| No codes listed |
| No codes listed |
Provider Responsibilities, Prior Authorization, and Documentation
Verify benefits; PA may be required per contract
Coverage determinations are based on the member's applicable contract language and may require verification; Wellmark will determine medical necessity only if the benefit exists and no contract exclusions apply. Prior authorization may be required per contract.
PA required when initial limits or step therapy trigger
Requests for extended‑release/long‑acting opioid agents require prior authorization when initial quantity limit criteria apply or when step therapy/claim rejection conditions are met; such requests will be routed to the PA unit for evaluation.
PA required for higher MME/day quantities
Prior authorization is required for coverage of ER opioid quantities that correspond to ≥90 MME/day up to <200 MME/day, and for amounts ≥200 MME/day when applicable per the chart and FDA‑labeled dosing.
Post‑limit PA for strengths with initial limit = 0
Some drug strengths have an initial limit of zero and will be processed only via post‑limit prior authorization; the Opioid Analgesics ER Quantity Limits Chart identifies those strengths.
PA required when limits exceeded or no qualifying prior use
Prior authorization is required when initial quantity limits are exceeded or when the patient lacks qualifying recent opioid prescription history; patients meeting PA criteria for chronic pain may be approved for up to 6 months.
Reserve long‑acting opioids for failures/intolerance to alternatives
Long‑acting/extended‑release opioid formulations are reserved for patients for whom alternative treatments (non‑opioid analgesics or immediate‑release opioids) are ineffective, not tolerated, or otherwise inadequate.
Require prior IR/ER fill to meet initial step therapy
Initial step therapy requires documentation of a recent fill of at least an 8‑day supply of an immediate‑release (IR) opioid within the past 90 days or at least a 30‑day supply of an extended‑release (ER) opioid within the past 90 days; absent this, the claim will reject and PA is required.
Step therapy required for <90 MME/day coverage
Step therapy must be met to qualify for coverage without prior authorization at the initial supply level corresponding to <90 MME/day.
Prior-use expectations for ER opioid coverage
ER opioids are intended for patients who have tried and not achieved adequate pain control with alternatives; prior use of IR opioids or stability on an ER opioid influences initial quantity limit application.
Exceptions: cancer, sickle cell disease, palliative/hospice
Step therapy criteria and post‑limit quantity rules do not apply for patients identified as having cancer, sickle cell disease, or receiving palliative or hospice care; those requests are routed to the prescription benefit and exempted from step therapy/post‑limit limits.
Verify member benefits and contractual applicability
Verify member benefits and applicable contract language at the time of service; Wellmark will determine medical necessity only if the benefit exists and no contract exclusions apply.
Document monitoring and reassessment plan
Document that the patient can safely take the requested dose, has been evaluated, will be monitored for opioid use disorder, and a pain reassessment plan is in place (first month after initiation/dose increase and every 3 months thereafter).
Document safety, opioid history, and monitoring plans
Provide documentation that the patient can safely take the requested dose based on opioid history and that monitoring for opioid use disorder and periodic pain/function reassessment will occur per the stated schedule.
Document indication: chronic pain or qualifying diagnosis
If prescribing for chronic pain, document that the pain is chronic (generally >3 months) or that the prescription is for cancer, sickle cell disease, a terminal condition, or for hospice/palliative care.
Document prior therapy for continuation requests
For continuation requests, document the patient has been receiving an ER opioid for at least 30 days or has taken an immediate‑release opioid for at least one week.
Submit prior prescription claim history and diagnosis evidence
Include prescription claim history showing prior fills (e.g., ≥8‑day IR supply or ≥30‑day ER supply within past 90 days) and any diagnosis/supporting profile entries (cancer, sickle cell disease, palliative care, hospice) to determine benefit routing and quantity limit application.
Required documentation for PA and quantities above limits
Provide required documentation of recent prescription claim history (IR supply ≥8 days or ER supply ≥30 days within past 90 days) and justification when requesting quantities above initial limits; for chronic pain PA approvals may be granted for up to 6 months.
Risk: benefit not applicable or excluded by contract
Benefits may be denied if the member's contract does not include coverage for the requested service or if exclusions/limitations apply; coverage and medical necessity are determined only if the benefit exists and no contract exclusions apply.
Claim rejection if prior-fill thresholds not met
Claims will reject and require prior authorization if the patient does not have at least an 8‑day supply of an IR opioid or at least a 30‑day supply of an ER opioid in the prior 90 days.
Risk: denial for exceeding MME/day or supply limits
Requests exceeding the listed MME/day quantity limits or supply quantities that do not meet prior authorization conditions may be denied.
Methadone not covered for detox/maintenance treatment
Methadone prescribed for detoxification or as maintenance treatment for opioid/substance use disorder is not eligible under these prescribing conditions and is subject to federal distribution/use requirements (42 CFR) and separate dispensing rules.
Prior‑use requirement triggers PA and claim rejection
A claim will reject if the patient does not have at least an 8‑day supply of an IR opioid or at least a 30‑day supply of an ER opioid in the prior 90 days, triggering the requirement for prior authorization.
Reject if insufficient recent opioid prescription history
Claims will reject if the patient lacks required recent opioid prescription history (at least an 8‑day IR supply or a 30‑day ER supply in the past 90 days); the message will indicate that prior authorization is required.
Reject for exceeding initial quantity limit — PA required
The system will reject requests that exceed the initial quantity limit and prompt that a prior authorization is required; such requests must then be submitted for PA review.
Conservative Treatment and Prior Trial Expectations
Trial of alternative analgesics or immediate-release opioids prior to ER/long-acting opioid use when appropriate.
Consistent statement across multiple product limitations of use.
Definitions and Key Terms
Quantity and Frequency Limits for ER Opioids
Imaging Requirements
No action required (none).
Background
Background: This policy summarizes indications and repeated limitations of use for multiple long‑acting opioid formulations and emphasizes that these agents should be reserved for opioid‑tolerant patients or patients for whom alternatives are ineffective or not tolerated. The policy repeatedly notes the increased risks of addiction, misuse, overdose, and death with long‑acting opioids and clarifies that these products are not appropriate for as‑needed use.
Not Covered / Exclusions
Not covered: Use of long‑acting/extended‑release opioid formulations as as‑needed (PRN) analgesics is not covered under this policy. Also not covered under these outpatient prescribing conditions is the use of methadone for detoxification or as maintenance therapy for opioid addiction outside of certified opioid treatment programs; such use is subject to federal distribution requirements (42 CFR) and program‑specific processes.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.